BRAF and melanoma: In the HTDS, PDXCs derived from patients harbouring a BRAF-mutant melanoma that progressed on BRAF and MEK inhibitors showed resistance to these treatments, whereas PDXCs derived from treatment-naive patients showed a marked response to these treatments.